Mass General Brigham Spins Out Generative AI Startup

Mass General Brigham has officially launched a new generative AI startup named AIwithCare, aimed at transforming clinical trial recruitment processes. This new company was spun out to commercialize a generative AI-powered screening platform that interprets both structured and unstructured clinical data, significantly enhancing patient screening accuracy and speed for clinical trials.

Dr. A.J. Blood, a cardiologist at Mass General Brigham and CEO of AIwithCare, highlighted that traditional trial recruitment relies heavily on manual chart reviews by clinically trained staff, which is a time-consuming and labor-intensive task.

The generative AI engine developed by Dr. Blood and his research team aims to alleviate this burden, as evidenced by a study published in JAMA, which found that the enrollment rate using AIwithCare was nearly double that of conventional methods.

The platform is designed to evaluate patients against complex trial inclusion and exclusion criteria automatically, moving beyond merely relying on potentially inaccurate billing codes. AIwithCare is now positioning itself against competitors like Antidote, Tempus, and Trialspark, while also planning to extend its applications to safety, quality, and clinical operations within healthcare settings.

The goal is to not only streamline clinical trial recruitment but also revolutionize how hospitals and research entities utilize AI to enhance patient care and operational efficiency.